ProPhase Labs, Inc. Accounts Payable
ProPhase Labs, Inc. (PRPH) had Accounts Payable of $15.03 million as of 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2025-08-13
- 2025-06-30: Accounts Payable, Current $15.03M.
- 2025-03-31: Accounts Payable, Current $13.33M.
- 2024-12-31: Accounts Payable, Current $13.72M.
- 2024-09-30: Accounts Payable, Current $15.46M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2025-06-30 | $15.03M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $13.33M 10-Q · filed 2025-05-20 | |
| 2024-12-31 | $13.72M 10-Q · filed 2025-08-13 | |
| 2024-09-30 | $15.46M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $13.63M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $11.76M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $8.64M 10-K · filed 2025-04-01 | $9.38M 10-K · filed 2024-03-29 |
| 2023-09-30 | $5.47M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $4.79M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $4.87M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $5.91M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $1.54M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $4.45M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $8.20M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $7.03M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $2.39M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $7.11M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $7.78M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $3.77M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $836.00K 10-Q · filed 2020-11-19 | |
| 2020-06-30 | $844.00K 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $695.00K 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $432.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | $374.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $442.00K 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $258.00K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $437.00K 10-K · filed 2020-03-26 | |
| 2018-09-30 | $380.00K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $445.00K 10-Q · filed 2018-08-20 | |
| 2018-03-31 | $544.00K 10-Q/A · filed 2018-08-20 | |
| 2017-12-31 | $562.00K 10-K · filed 2019-03-26 | |
| 2017-09-30 | $503.00K 10-Q/A · filed 2018-08-20 | |
| 2017-06-30 | $916.00K 10-Q/A · filed 2018-08-20 | |
| 2017-03-31 | $559.00K 10-Q/A · filed 2018-08-20 | |
| 2016-12-31 | $2.16M 10-Q/A · filed 2018-08-20 | |
| 2016-09-30 | $1.97M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $1.37M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $1.56M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $990.00K 10-K · filed 2017-02-24 | |
| 2015-09-30 | $919.00K 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $646.00K 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $1.23M 10-Q · filed 2015-05-13 | |
| 2014-12-31 | $667.00K 10-K · filed 2016-03-29 | |
| 2014-09-30 | $2.11M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $1.40M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $992.00K 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $1.01M 10-K · filed 2015-03-27 | |
| 2013-09-30 | $1.30M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $1.03M 10-Q · filed 2013-08-13 | |
| 2013-03-31 | $678.00K 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $1.30M 10-K · filed 2014-03-27 | |
| 2012-09-30 | $537.00K 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $526.00K 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $822.00K 10-Q · filed 2012-05-11 | |
| 2011-12-31 | $885.00K 10-K · filed 2013-03-28 | |
| 2011-09-30 | $726.00K 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $131.00K 10-Q · filed 2011-08-12 | |
| 2010-12-31 | $489.00K 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |